9. Patients should have discontinued therapy with imatinib, dasatinib, nilotinib, ponatinib, omacetaxine or other anti-leukemia therapy (except hydroxyurea) >/= 48 hours prior to start of study therapy and recovered from any toxicity due to these therapies to grade </= 1. Hydroxyurea may be received up to the time of enrollment and for the first 6 weeks of study treatment if necessary.